摘要
目的:了解我国基本药物价格水平,针对性提出政策建议。方法:以世界卫生组织和国际健康行动机构提出的标准方法为基础,对其针对我国国情进行改进,分别对我国药品价格与国际参考价格、原研药与仿制药以及公立机构与私立机构药品价格进行比较研究。结果:30种被调查药品的中位价格比为2.97,14种原研药为30.28。在本次调查中,有10.3%的公立医疗机构和46.7%的私立药店药品价格在世界卫生组织推荐的可接受范围内。结论:我国基本药物的价格水平偏高,尤其是原研药。中国公立机构药品价格较私立机构高,原研药价格通常远高于仿制药。
Objective To investigate the essential drugs′ price in China,and put forward objective policy suggestions.Methods According to Chinese status,the standard methods proposed by the World Health Organization and Health Action International were improved.Then,local drugs′ price was compared with international reference price.And drug prices of innovator brand and generic drugs,public and private institutions were comparatively studied.Results The price median ratio of 30 types of drugs was 2.97.And for 14 types of innovator brand drugs,it was 30.28.10.3% of drugs′ price in public institutions and 46.7% of drugs′ price in private institutions were within the acceptable range recommended by the World Health Organization.Conclusion The prices of essential drugs in China were quite high,especially that of innovator brand drugs.Prices of drugs in public institutions were higher than those in private institutions.And prices of innovator brand drugs were much more expensive than those of generic drugs.
出处
《中国卫生事业管理》
北大核心
2011年第4期266-267,309,共3页
Chinese Health Service Management
